Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Squamous cell carcinoma~ * Adenocarcinoma, including bronchoalveolar cell carcinoma~ * Large cell anaplastic carcinoma, including giant and clear cell carcinoma~* Inoperable stage IIIA or IIIB disease~* No direct invasion of vertebral body~  * Tumors adjacent to a vertebral body without bone invasion allowed if all gross disease can be encompassed in radiotherapy boost field~* Contralateral mediastinal disease (N3) allowed if all gross disease can be encompassed in radiotherapy boost field~* No scalene, supraclavicular, or contralateral hilar node involvement~* Transudate, cytologically negative, non-bloody pleural effusion allowed if it can be encompassed in radiotherapy field~  * No exudative, bloody, or cytologically malignant pleural effusion~ * Evidence of pleural effusion by chest CT scan but not chest x-ray that is too small to tap allowed~* At least 1 unidimensionally measurable lesion~  * At least 20 mm by conventional techniques OR~ * At least 10 mm by spiral CT scan~ * The following are not considered measurable disease:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Abdominal masses that are not confirmed and followed by imaging techniques~   * Cystic lesions~   * Tumor lesions in a previously irradiated field~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin less than 1.5 mg/dL~* AST less than 2 times upper limit of normal~Renal:~* Creatinine clearance 20-130 mL/min for females~* Creatinine clearance 20-150 mL/min for males~Pulmonary:~* FEV1 at least 1.2 L~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other currently active malignancy (defined as completed prior therapy and considered to be at less than 30% risk of relapse) except non-melanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for NSCLC~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent hormonal therapy except steroids for adrenal failure or septic shock, hormones for non-disease-related conditions (e.g., insulin for diabetes), or glucocorticosteroids as antiemetics~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy for NSCLC~Surgery:~* At least 2 weeks since prior exploratory thoracotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel + Carboplatin (Type: EXPERIMENTAL): Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
- Gemcitabine + Carboplatin (Type: EXPERIMENTAL): Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).